Adlai Nortye Group Ltd. (ANL)
ANL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1944552/000121390026042520/0001213900-26-042520-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ANL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Cayman Islands |
| IPO year | 2023 |
| SEC CIK | 0001944552 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Singapore |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $5.0M |
| Net income | -$35.5M |
| Operating income | -$35.7M |
| Net margin | -710.6% |
| Operating margin | -714.0% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $8.1M |
| Total assets | $34.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 129.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-10 |
| Cash and burn | $8.1M cash; operating cash flow -$8.4M a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Mazars USA LLP, New York, New York, United States | PCAOB Form AP 2024-04-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $248K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $5.0M | -$35.5M | -$33.5M | $8.1M | $24.6M | $5.0M | 20-F 2026-04-10 |
| FY 2024 2024-12-31 | Not filed | -$51.9M | -$51.8M | $60.9M | $26.3M | Needs four quarters | 20-F/A 2025-05-12 |
| FY 2023 2023-12-31 | $5.0M | -$109.2M | -$56.7M | $91.5M | $30.4M | $5.0M | 20-F/A 2025-05-12 |
| FY 2022 2022-12-31 | Not filed | -$58.8M | -$43.2M | $42.8M | $4.3M | Needs four quarters | 20-F/A 2025-05-12 |
| FY 2021 2021-12-31 | $45.7M | -$56.7M | -$3.0M | $64.1M | $10.5M | $45.7M | 20-F/A 2025-02-14 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 | POS AM | 2026-09-11 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-04-10 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-10-28 |
Source: SEC EDGAR submissions feed, 114 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.2% |
| 1 month | -9.7% |
| 3 months | -17.5% |
| Year to date | +647.2% |
| 1 year | +602.6% |
| From 52-week high | -36.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OLMA | Olema Oncology Inc. | $7.36 | -2.65% | $644.8M |
| BCAX | Bicara Therapeutics Inc. | $9.75 | -2.69% | $647.3M |
| KURA | Kura Oncology Inc. | $7.09 | -8.75% | $651.4M |
| DSGN | Design Therapeutics Inc. | $9.92 | -5.25% | $635.2M |
| NVCT | Nuvectis Pharma Inc. | $19.11 | -5.58% | $657.2M |
| IMMX | Immix Biopharma Inc. | $7.48 | -4.59% | $626.9M |
| ALMS | Alumis Inc. | $5.14 | -8.21% | $667.3M |
| JANX | Janux Therapeutics Inc. | $10.92 | -3.96% | $668.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier